REGENXBIO to Present at Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) announced participation in two upcoming virtual investor conferences in December 2020. The company will host a pre-recorded fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference and a live webcast at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 11:45 a.m. ET. The pre-recorded chat is now available on REGENXBIO's website for 30 days. REGENXBIO focuses on gene therapy through its proprietary NAV Technology Platform, featuring over 100 AAV vectors for various therapeutic applications.

ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV^® Technology Platform, today announced it will present at the following December investor conferences, which will each be held in a virtual meeting format:

Piper Sandler 32^nd Annual Virtual Healthcare Conference
Fireside Chat: Pre-recorded

Evercore ISI 3^rd Annual HealthCONx Conference
Fireside Chat: Thursday, December 3, 2020 at 11:45 a.m. ET

The pre-recorded Piper Sandler fireside chat is currently available in the Investors section of REGENXBIO's website at www.regenxbio.com and will be available for approximately 30 days. A live webcast of the Evercore fireside chat can be accessed in the same section of REGENXBIO's website, and an archived replay will be available for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com

Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-upcoming-investor-conferences-301178926.html

SOURCE REGENXBIO Inc.

FAQ

What investor conferences is REGENXBIO participating in December 2020?

REGENXBIO will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference and the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020.

When is the Evercore ISI HealthCONx Conference for REGENXBIO?

The Evercore ISI HealthCONx Conference for REGENXBIO is scheduled for December 3, 2020, at 11:45 a.m. ET.

How can I access REGENXBIO's fireside chat?

You can access REGENXBIO's pre-recorded fireside chat on their official website, available for about 30 days.

What is the NAV Technology Platform from REGENXBIO?

REGENXBIO's NAV Technology Platform is a proprietary gene delivery platform consisting of over 100 AAV vectors used in developing various gene therapy candidates.

Where can I find more information about REGENXBIO?

More information about REGENXBIO Inc. can be found on their official website at www.regenxbio.com.